Development of drug-loaded particles for intraperitoneal therapy

2015 ◽  
pp. 333-344
Author(s):  
Ze Lu ◽  
M. Guillaume Wientjes ◽  
Jessie L.-S. Au
Keyword(s):  
Intraperitoneal Therapy

scholarly journals Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy

2014 ◽  
Vol 16 (3) ◽  
pp. 424-439 ◽  
Author(s):  
Jessie L.-S. Au ◽  
Peng Guo ◽  
Yue Gao ◽  
Ze Lu ◽  
Michael G. Wientjes ◽  
...  
Keyword(s):  
Intraperitoneal Therapy

Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3

1992 ◽  
Vol 47 (1) ◽  
pp. 102-109 ◽  
Author(s):  
Robert Buckman ◽  
Carlo de Angelis ◽  
Patricia Shaw ◽  
Al Covens ◽  
Ray Osborne ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Malignant Ascites ◽  
Intraperitoneal Therapy

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

1991 ◽  
Vol 9 (10) ◽  
pp. 1801-1805 ◽  
Author(s):  
M Markman ◽  
B Reichman ◽  
T Hakes ◽  
W Jones ◽  
J L Lewis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Small Volume ◽  
Recurrent Ovarian Cancer ◽  
Second Line ◽  
Front Line ◽  
Phase Ii Trials ◽  
Two Phase ◽  
Overall Response ◽  
Intraperitoneal Therapy

Phase II trials of second-line intraperitoneal (IP) cisplatin-based therapy in patients with ovarian cancer have demonstrated the ability of this approach to produce objective antitumor responses, including surgically defined complete responses (CRs), in individuals with persistent small-volume disease after front-line cisplatin-based intravenous (IV) treatment. To examine the influence of a prior response to systemic cisplatin on the activity of second-line IP cisplatin, we retrospectively analyzed two phase II trials of cisplatin-based IP therapy in persistent/recurrent ovarian cancer conducted at our institution. Of the 89 assessable patients on the two trials, 52 (58%) had previously responded to IV cisplatin. The overall response and CR rates to second-line IP cisplatin-based therapy in this previously responding population were 56% and 33%, respectively, compared with overall response and CR rates in the 37 nonresponders to IV cisplatin of 11% and 3%, respectively (P less than .001; chi 2, 1 df). In the 36 patients responding to systemic cisplatin and whose largest tumor mass measured less than 1 cm at IP cisplatin initiation, a 42% CR rate was observed, compared with a 7% CR rate in the 14 patients with the same bulk of disease who had previously failed to respond to systemic cisplatin (P less than .025). We conclude that a prior response to systemic cisplatin strongly influences the antineoplastic activity of second-line IP cisplatin in ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document